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Abstract
Global metabolomic profiling offers novel opportunities for the discovery of biomarkers and
for the elucidation of pathogenic mechanisms that might lead to the development of novel
therapies. GLUT1 deficiency syndrome (GLUT1-DS) is an inborn error of metabolism due to
reduced function of glucose transporter type 1. Clinical presentation of GLUT1-DS is hetero-
geneous and the disorder mirrors patients with epilepsy, movement disorders, or any parox-
ysmal events or unexplained neurological manifestation triggered by exercise or fasting.
The diagnostic biochemical hallmark of the disease is a reduced cerebrospinal fluid (CSF)/
blood glucose ratio and the only available treatment is ketogenic diet. This study aimed at
advancing our understanding of the biochemical perturbations in GLUT1-DS pathogenesis
through biochemical phenotyping and the treatment of GLUT1-DS with a ketogenic diet.
Metabolomic analysis of three CSF samples from GLUT1-DS patients not on ketogenic diet
was feasible inasmuch as CSF sampling was used for diagnosis before to start with keto-
genic diet. The analysis of plasma and urine samples obtained from GLUT1-DS patients
treated with a ketogenic diet showed alterations in lipid and amino acid profiles. While sub-
tle, these were consistent findings across the patients with GLUT1-DS on ketogenic diet,
suggesting impacts on mitochondrial physiology. Moreover, low levels of free carnitine were
present suggesting its consumption in GLUT1-DS on ketogenic diet. 3-hydroxybutyrate, 3-
hydroxybutyrylcarnitine, 3-methyladipate, and N-acetylglycine were identified as potential
biomarkers of GLUT1-DS on ketogenic diet. This is the first study to identify CSF, plasma,
and urine metabolites associated with GLUT1-DS, as well as biochemical changes
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Introduction
Metabolomic profiling is a semi-quantitative, unbiased analysis that looks at perturbations in
metabolism. Metabolomics can be used for the diagnosis of inborn errors of metabolism
(IEMs) enabling the simultaneous analysis of ~800 metabolites (amino acids, organic acids,
fatty acids, neurotransmitters, nucleotides, cofactors and vitamins, bile acids, and other mole-
cules<1,000 Da in molecular weight) within a single analysis [1]. Moreover, it is emerging as
a powerful tool to understand small molecule perturbations occurring because of an enzyme
defect and the relationship to the disease pathogenesis [2,3].
GLUT1 deficiency syndrome (GLUT1-DS) is an autosomal dominant, treatable neurologi-
cal disorder due to a deficiency of glucose transporter type 1 (GLUT1) with an estimated fre-
quency at approximately 1: 83,000 [4]. The GLUT1 transporter is encoded by the solute carrier
family 2 member 1 (SLC2A1) gene and SLC2A1 heterozygous pathogenic mutations cause
GLUT1-DS. GLUT1 specifically transports glucose across the blood-brain barrier; only five
percent of glucose is transported across the blood-brain barrier by passive diffusion [5]. Defi-
ciency of GLUT1 results in hypoglycorrhachia and impairment of cerebral metabolism. Neu-
rons in the superficial layers of cerebral cortex and hippocampus followed by neurons in basal
ganglia and thalamus are primarily affected by lack of glucose. Hypoglycemia-induced neuro-
nal death is not a direct result of energy failure but involves additional mechanisms such as
glutamate neurotoxicity or toxic levels of aspartate and/or adenosine [5–7].
Untreated GLUT1-DS has a broad clinical presentation comprising intellectual disability,
movement disorder, acquired microcephaly and seizures. Recently, dominant SLC2A1 muta-
tions were found in various forms of epilepsy, including genetic generalized epilepsy (GGE).
In clinical practice, the clinically available distinctive biomarker for GLUT1-DS is a low con-
centration of glucose in cerebrospinal fluid (CSF) (<50 mg/dl or CSF-to-blood glucose ratio
<0.60). Early diagnosis is critical for an effective etiological therapy.
Among IEMs, GLUT1-DS is unique because it is treatable and earlier treatment results in a
better prognosis. However, it is not routinely tested by newborn screening. GLUT1-DS treat-
ment is based on ketogenic diet (KD), an isocaloric, high fat, low-carbohydrate diet inducing
production of ketone bodies (beta-hydroxybutyrate and acetoacetate) mimicking the biochem-
ical changes occurring in periods of fasting. KD is also used as adjuvant therapy in patients
with drug-resistant epilepsy [6, 7]. The diet consists of 3–4 g of fat to every 1 g of carbohydrate
and protein combined (classic 3:1 or 4:1 KD). Although KD is the first choice of treatment for
GLUT1-DS, in about 20% of patients, this diet can lose its effectiveness over time [7]. Further
studies on pathophysiological mechanisms of KD are needed to develop novel therapeutic
strategies.
In this study, we describe the identification of biomarkers associated with GLUT1-DS plus
KD. We initially performed ultra-high performance liquid chromatography-tandem mass
spectrometry on a single CSF sample from a subject diagnosed with GLUT1-DS and per-
formed subsequent analyses on subjects diagnosed with GLUT1-DS and using KD interven-
tion. Due to timing of metabolomics platform advancements, two different configurations
were used, but consistent biochemical alterations were identified between the methods that
aligned with the changes in phenotype and clinical appearance of the patients. To our knowl-
edge, this is the first application of metabolomics in patients diagnosed with GLUT1-DS.
Metabolomic profile of ketogenic diet in GLUT1 deficiency syndrome
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Material and methods
Participants and clinical data
Nine patients with a diagnosis of GLUT1-DS were enrolled in the study based on CSF glucose-
to–blood glucose ratio <0.6 and the presence of a pathogenic SLC2A1 mutation. 8 Patients
with GLUT1-DS were referred to our clinical laboratory for biochemical testing or were
enrolled in our study at the Department of Child Neurology and Psychiatry, Fondazione
IRCCS Istituto Neurologico C. Mondino in Pavia, Italy (patients previously published [8])
while the 9th patient has been followed by the Department of Medical Genetics & Genomic
Medicine, Saint Peter’s University Hospital, New Brunswick, USA. Table 1 outlines demo-
graphics, clinical, biochemical and molecular information for each of the patients, as well as
the ketogenic diet intervention for each patient at the time the biofluid was obtained. Three of
the nine patients were not on ketogenic diet, while the remaining six patients were on KD. For
the three patients, not on KD, only CSF samples were available.
This study received institutional review board approval at either Baylor College of Medicine
or at Federico II University, where the investigations complied with the Declaration of Hel-
sinki, and parents provided written informed consent before the beginning the study. All
patients underwent a lumbar puncture in the fasting state (after 5–6 h of fasting) either as part
of standard medical care or as part of this the initial enrollment in this study. Blood samples
for glucose measurement were obtained immediately before the lumbar procedure to avoid
stress-related hyperglycemia. A CSF-to–blood glucose ratio <0.6 was considered suspicious
for GLUT1-DS. Confirmation of the diagnosis was obtained by SLC2A1 mutation analysis.
Molecular analysis
Molecular analysis of SLC2A1 was performed clinically or under a research protocol, including
Sanger sequencing of all exons and flanking donor/acceptor sequences, as well as deletion/
duplication analysis via multiplex ligation-dependent probe amplification (MLPA) as previ-
ously described [4].
Global metabolomic profiling
Metabolomic profiling was performed by Baylor Genetics Laboratories (Houston, TX) and
Metabolon, Inc (Durham, NC) as described previously [1,9,10] for plasma, urine, and CSF
using two different platform configurations. For the both configurations, small molecules were
extracted from 100 of ul of sample in an 80% methanol solution.
The first platform configuration consisted of four chromatographic analyses: GC-MS,
LC-MS/MS in positive mode (LCMS Pos), LC-MS/MS in negative mode (LCMS Neg), and a
LC-MS/MS Polar method (LCMS Pol). GC-MS was performed on bistrimethyl-silyl-trifluor-
oacetamide derivatized analytes using a Trace DSQ fast-scanning single-quadrupole mass
spectrometer (Thermo-Finnigan). For LC/MS Neg and LCMS Pos methods, chromatographic
separation was completed using an ACQUITY UPLC (Waters) equipped with a Waters BEH
C18 column followed by analysis with an Orbitrap Elite high resolution mass spectrometer
(Thermo-Finnigan).
The second configuration utilized the same mass spectrometry methods but utilized the fol-
lowing chromatographic methods: LCMS Neg (same as the previous configuration), LCMS
Pol (same as previous configuration), and LCMS positive ion method focusing on lipophilic
compounds (LCMS Pos Lipid) and LCMS positive ion method focusing on polar compounds
(LCMS Pos Polar). In both configurations, metabolites were identified with known chemical
structure by matching the ions’ chromatographic retention index, accurate mass, and mass
Metabolomic profile of ketogenic diet in GLUT1 deficiency syndrome
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Table 1. Clinical features of patients with GLUT1-DS.
Pt Sample ID Gender Age
(years)*
CSF /
Plasma
Glucose
SLC2A1 variant
NM_006516.2
HC
(%)
IQ Seizure onset
(months)
and type
MD Other clinical
features
AEDs KD
type
1 BIEM-
00796
Plasma
BIEM-
00797
Urine
M 11 0.51 p.Arg223Trp <25 82 30, FCS PED M OXC 2:1
2 BIEM-
00784
Plasma
BIEM-
00785 Urine
F 2 0.37 p.Arg249Ala
fs131X
25–
50
50 9, MAS / / / 1.6:1
3 BIEM-
00786
Plasma
BIEM-
00787
urine
F 7 NA p.Asn34Ser >50 93 NA, ABS / / ETS 3:1
4 BIEM-
00791
plasma
BIEM-
00792
Urine
F 7 0.36 p.Leu124TrpfsX12 >50 55 6, MS / O CLB 3:1
5 BIEM-
00788
Plasma
F 13 0.42 p.Thr295Met
/pT295M9
25 79 24, ABS PED O VPA ETS 4:1
6 BIEM-
00789
plasma
BIEM-
00790
Urine
M 19 0.39 p.Arg223Thr <10 50 17, MAS / O LEV VPA 2:1
7 BIEM-
00782
plasma
BIEM-
00783
CSF
M 10 0.5 p.Leu67Pro >50 99 / PED W / /
8 BIEM-
00794
plasma
BIEM-
00795
CSF
F 12 NA p.Thr9Met >50 102 84, ABS / / ETS- started
after CSF
sampling
/
9 604266
CSF
M Newborn 0.32 p.Arg153Gly 20 / 9 days (0.3
months), FCS
/ small, unilateral
preauricular tag
LEV- started
after CSF
sampling
Clinical and molecular detail for each patient are depicted in Table 1.
F. female; M. male; Ratio. CSF/blood glucose ratio; NA. not available; Y. yes; N. no; HC. head circumference; m. months; ABS. absence seizure; FCS.
Focal complex seizures; MAS. myoclonic atonic seizures. MS. myoclonic seizures; MD. movement disorder; C. chronic; PED. paroxismal exertion-induced
dyskinesia; M. migraine; O oculogiric crises; W. weakness; KD. ketogenic diet; OXC. oxacarbazepine; ETS. ethosuximide; CLB. Clobazam; VPA. valproic
acid; LEV. Levetiracetam.
* Age at diagnosis of disease
https://doi.org/10.1371/journal.pone.0184022.t001
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spectral fragmentation signatures with reference library entries created from authentic stan-
dard metabolites under the identical analytical procedure as the experimental samples [11].
Currently, the reference library contains entries for ~2500 unique human metabolites.
Semi-quantitative analysis was achieved by comparing patient samples to a set of invariant
anchor specimen included in each batch. Raw spectral intensity values were normalized to the
anchor samples log transformed and compared to a normal reference population to generate
z-score values. The reference population was a pediatric, randomly sampled population that
was matched for age, diet and gender for this comparison. Rare compounds are those analytes
detected in the patient specimen but only rarely seen in the reference population (<5% of all
patients tested). Median raw intensity values were calculated for all analytes identified in2/3
of the anchor specimen and these median values were then used to normalize corresponding
analyte raw intensity values in patient specimen. Analytes not identified in 2/3 or more of the
anchor specimens were excluded from analysis. Anchor adjusted analyte values were scaled to
the median anchor adjusted analyte values of all previous specimens analyzed to date, missing
values were imputed using the minimum detected value and the data were log-transformed.
Data collected from samples were normalized to creatinine. Z-scores were calculated using the
mean and standard deviation of the entire median-scaled log-transformed dataset.
Statistical analysis
In the single-metabolite analysis, we assessed whether study-subject metabolite levels were
altered compared to background by using single-group t-test on z-scores. In the pathway anal-
ysis, we assessed whether multiple metabolite levels within a pathway were altered. To this
aim, we calculated the mean values for all metabolites and applied a Kruskal-Wallis analysis
comparing the mean levels of pathway-metabolites versus non-pathway-metabolites. Statistical
analysis was performed by using the R package for statistical computing version 3.3.1. Analysis
with p-values below 0.001 were considered as statistically significant. Box-plots were designed
with ggplot2 R-package: the solid line within the box represents the median; top and bottom
lines of the box represent 75th and 25th percentiles respectively; top and bottom ends of whis-
kers represent the 75th percentile plus the 1.5  Inter-Quartile Range (IQR) and 25th percentile
minus the 1.5IQR respectively; dots outside the whiskers represents outlier values.
Results
Metabolomic studies in GLUT1-DS CSF
Molecules with Z-scores above or below ±2 are listed in S1 Table. Metabolomic analysis identi-
fied 292 compounds in the CSF of Patient 9, of which 38 had significant Z-score values>2 or
<-2. The most significant results were the detection of low levels of fructose (Z-score –2.8),
mannose (Z-score –2.86) and glucose (Z-score –3.2), and high levels of glutamine (Z-score
+3.98) and inosine (Z-score +3.91) (Fig 1). We performed traditional clinical CSF amino acid
evaluation on the same CSF sample submitted for metabolomic profiling; however, no amino
acid abnormalities were detected (glutamine 455.144 nM/ml, normal range 161–533 and glu-
tamic acid 0 nM/ml, normal range 0–117).
By the time additional CSF samples were acquired, two in total, from subjects with
GLUT1-DS, there was a change in the metabolomics platform configuration; the information
regarding the version of the platform utilized for each sample is outlined in Table 2. There was
a consistent profile observed (Table 2) with 321 and 322 named metabolic compounds identi-
fied. Comparing the biochemical profiles for these two patients to our reference population
revealed significantly lower glycerol 3-phosphate (Gro3P) levels and significantly elevated
Metabolomic profile of ketogenic diet in GLUT1 deficiency syndrome
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isocitrate levels (Table 2). No significant changes in amino acids or neurotransmitters were
found in the CSF from these two subjects.
Metabolomic studies on plasma samples from GLUT1-DS patients on
ketogenic diet (KD)
Metabolomic analyses of plasma from the six GLUT1-DS patients on KD identified an average
of 633 metabolites. Each patient’s ketogenic diet intervention is outlined in Table 1. The
Fig 1. Metabolomic profiling identifies significantly altered levels of molecules in cerebrospinal fluid. Analytes significantly outside of the normal
range are reported (relative to the general population. Z-scores <-2 or >2 are considered significant. A boxplot demonstrating analytes from the affected
patient (represented by red circle) identified in the metabolomics profile with significant deviation from the normal range are shown. Elevations of glutamine (Z-
score +3.98) and inosine (Z-score +3.91), along with reductions of glucose (Z-score -3.2), fructose (Z-score -2.8), and mannose (Z-score -2.86), are indicated.
A complete listing of significantly altered analytes identified in the metabolomics analysis is provided in S1, S2 and S3 Tables.
https://doi.org/10.1371/journal.pone.0184022.g001
Table 2. Z-scores of carbohydrate levels in CSF from patients diagnosed with GLUT1-DS not being treated with a KD.
Platform Version Version 1 Version 2
Carbohydrate 604266 (Patient 9) BIEM-00783 (Patient 7) BIEM-00795 (Patient 8)
Glucose -3.3 -0.69 -0.61
Fructose -2.8 -0.03 -1.11
Mannose -2.86 0.15 0.02
Glycerol 3-phosphate ND -3.69 -2.34
Isocitrate ND 1.85 2.20
ND–Not detected
https://doi.org/10.1371/journal.pone.0184022.t002
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examination of the Z-scores for each patient revealed several biochemical elevated across most
of the plasma samples (Table 3). These include 3-hydroxybutyrate and 3-hydroxybutyrylcarni-
tine as well as 3-methyladipate and N-acetylglycine. All plasma samples had matched urine
samples and 3-hydroxybutyrate, 3-methyladipate, and N-acetylglycine showed elevated levels
in urine (Table 3). Changes associated with individual carbohydrates did not show Z-scores
<-2, but several molecules did show decreased levels in plasma (Table 4).
We next analyzed entire pathways and subpathways to interrogate perturbations associ-
ated with entire pathways. The most affected superpathway was lipid metabolism (Table 5).
Considering all the biochemicals identified and grouped into sub-pathways: long chain fatty
acid, phospholipid, acylcarnitine and sphingolipid metabolism were significantly disturbed
in GLUT1-DS patients on ketogenic diet (Table 6). The super-pathway analysis confirmed
that lipids were the most significantly modified compounds in GLUT1-DS patients on KD
(Table 5).
Carnitine and energy metabolism. Free carnitine and carnitine conjugates of GLUT1-DS
on KD are shown in Table 7. Overall, those acylcarnitines linked to fatty acid metabolism
showed higher levels in subjects on KD whereas those acylcarnitines linked to amino acid
metabolism showed decreased levels. Specifically, amino acid-related acylcarnitines, 2-methyl-
malonyl carnitine, isovalerylcarnitine, propionylcarnitine, isobutyrylcarnitine, glutarylcarni-
tine, carnitine and 2-methylbutyrylcarnitine z-scores for GLUT1-DS patients on KD were
significantly lower than for controls. Succinylcarnitine, a molecule representing an anaplerotic
entry point into the tricarboxylic acid (TCA) cycle and where the metabolism of several amino
acids feeds into the TCA cycle showed decreased levels. Moreover 3-hydroxybutyrylcarnitine,
oleoylcarnitine, stearoylcarnitine were significantly higher in patients with GLUT1-DS on KD
(Fig 2A and 2B). As expected 3-hydroxybutyrate (BHBA) was significantly (p = 1.86 e-05)
Table 3. Z-scores for consistently elevated compounds in plasma and urine from GLUT1-DS on KD diet.
Individual
Patient
Sample ID Matrix 3-hydroxybutyrate 3-hydroxy
butyrylcarnitine
3-methyl
adipate
N-acetyglycine
1 BIEM-00796 EDTA Plasma 1.11 1.36 1.37 1.58
BIEM-00797 Urine 3.64 0.91 0.85 -0.59
2 BIEM-00784 EDTA Plasma 3.22 2.13 1.63 2.25
BIEM-00785 Urine 4.93 1.04 1.95 1.72
3 BIEM-00786 EDTA Plasma 3.59 2.82 2.96 2.39
BIEM-00787 Urine 6.36 0.42 2.38 3.15
4 BIEM-00791 EDTA Plasma 3.36 2.31 2.09 1.99
BIEM-00792 Urine 6.19 0.72 1.75 3.98
5 BIEM-00788 EDTA Plasma 3.38 1.77 2.24 2.50
6 BIEM-00789 EDTA Plasma 2.40 1.56 2.55 3.68
BIEM-00790 Urine 4.09 0.07 2.36 1.03
7 BIEM-00783 CSF Sample acquired prior to initiation of KD
BIEM-
00782*
Not EDTA Plasma NA NA NA NA
8 BIEM-00795 CSF Sample acquired prior to initiation of KD
BIEM-00794 Urine 0.04 0.59 0.94 1.45
BIEM-
00793*
Improperly handled EDTA
Plasma
NA NA NA NA
* Sample not included in analysis but listed for completion. Results leading to non-EDTA plasma and/or improper handling conclusion identified after data
acquisition.
https://doi.org/10.1371/journal.pone.0184022.t003
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elevated in plasma with an average z-score of 2.46 (p = 1.86 e-05) in individuals on ketogenic
diet. Although not all metabolites showed large perturbations, all of them showed consistent
directional changes suggesting the overall pathway was affected.
Long and medium-chain fatty acids. 8-hydroxyoctanoate, an octanoate derivative,
showed significantly lower values in GLUT1-DS patients in both plasma and urine on KD ver-
sus controls (p = 1.28 e-12), while other long-chain and medium-chain fatty acids showed sig-
nificantly (p<0.01) higher values in GLUT1-DS patients versus controls including: erucate
(22:1n9), eicosenoate (20:1), nonadecenoate (19:1n9), nonadecanoate (19:0), oleate/vaccenate
(18:1), 10-heptadecenoate (17:1n7), margarate (17:0), palmitoleate (16:1n7), palmitate (16:0),
myristoleate (14:1n5), myristate (14:0), 5-dodecenoate (12:1n7), and 10-undecenoate (11:1n1)
(S2 and S3 Tables).
Discussion
Reduced brain glucose transport associated with GLUT1 lowered activity or deficiency is the
hallmark of GLUT1-DS. Metabolomic profiling, the systematic study of small-molecule prod-
ucts of biochemical pathways has been used to predict diagnosis and monitor different meta-
bolic disorders [1,3,12–15]. We applied an untargeted metabolomics profiling approach on
both plasma and CSF samples from GLUT1-DS patients toward unraveling metabolic mecha-
nisms and biomarkers implicated in this disorder.
Currently, the routine diagnostic tools in clinical use for GLUT1-DS are low glucose in CSF
and a reduced CSF glucose to blood glucose ratio. Glucose values can vary depending on age
[16–18], and screening for glucose levels versus a pediatric-matched population can identify
perturbations in metabolites, such as carbohydrate metabolism, to identify signatures of dis-
ease (Table 2). The metabolomics approach in three CSF samples of GLUT1-DS not on keto-
genic diet patients was applied to achieve a more comprehensive mirror of glucose-dependent
Table 4. Carbohydrate levels in plasma from patients diagnosed with GLUT1-DS and taking a KD.
Carbohydrate Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Maltose -1.380 -1.376 -1.377 -1.375 -1.379 -1.379
Sucrose -1.279 -1.275 -1.279 -1.276 -1.279 -1.275
Lactose -0.534 -0.533 -0.535 -0.530 -0.535 -0.535
Mannitol/sorbitol -1.681 -1.477 -1.544 -0.757 -1.327 -1.606
N-acetylglucoseamine / N-acetylgalactosamine 0.453 0.801 0.324 0.449 0.332 0.511
Galactonate -0.923 -1.246 -1.416 -1.232 -1.421 0.192
3-phosphoglycerate 0.064 -0.959 -0.969 -1.682 -0.054 -1.090
N-acetylneuraminate -1.383 -0.243 -0.940 -1.119 -2.863 -0.028
https://doi.org/10.1371/journal.pone.0184022.t004
Table 5. Super-pathways modified in GLUT1DS patients on ketogenic diet.
SUPER_PATHWAY Number p_value
Lipid 305 7.90 e-06
Carbohydrate 22 0.023
Amino Acid 147 0.060
Cofactors and Vitamins 17 0.023
Xenobiotics 71 0.099
Nucleotide 28 0.714
Energy 8 0.030
Peptide 34 0.034
https://doi.org/10.1371/journal.pone.0184022.t005
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pathways in the brain. In the analysis of the initial sample, we identified significantly decreased
levels of glucose, fructose, and mannose with elevated levels of inosine and glutamine (Fig 1).
The analysis of two subsequent CSF samples revealed decreased levels of most TCA cycle inter-
mediates, elevated isocitrate, and decreased glycerol-3-phosphate (Table 2). The differences in
biochemicals detected on the two platforms can be attributed to the different chromatography
components of each platform; version 1 contained one LC/MS pos method and version 2 con-
tained two LC/MS pos methods. Increased isocitrate levels in CSF may reflect low enzyme
activity of isocitrate dehydrogenase, a NADP+-consuming enzyme. Glycerol-3-phosphate has
Table 6. Sub-pathways analysis based on individual metabolites perturbation in 6 GLUT1-DS patients on ketogenic diet.
SUB_PATHWAY # compounds in subpathway SUPER PATHWAY p_value
Long Chain Fatty Acid 13 Lipid 2.15 e-08
Phospholipid Metabolism 51 Lipid 3.49 e-07
Fatty Acid Metabolism(Acylcarnitine) 15 Lipid 1.34 e-05
Sphingolipid Metabolism 23 Lipid 0.0007
Fatty Acid. Monohydroxy 13 Lipid 0.001
Polyunsaturated Fatty Acid (n3 and n6) 14 Lipid 0.0018
Endocannabinoid 5 Lipid 0.009
Polyamine Metabolism 5 Amino Acid 0.011
Lysolipid 48 Lipid 0.015
Steroid 17 Lipid 0.016
Fatty Acid. Branched 2 Lipid 0.019
Fatty Acid. Amide 3 Lipid 0.030
Fatty Acid Metabolism (Acylglycine) 2 Lipid 0.030
Plasmalogen 16 Lipid 0.038
TCA Cycle 7 Energy 0.039
Nicotinate and Nicotinamide Metabolism 5 Cofactors and Vitamins 0.040
https://doi.org/10.1371/journal.pone.0184022.t006
Table 7. Significant free carnitine and carnitine derivatives for 6 patients with GLUT1-DS patients.
Biochemical HMDB SUPER PATHWAY SUBPATHWAY P value Average z-score
Carnitine HMDB00062 Lipid Carnitine Metabolism 0.0100 -1.537
3-hydroxybutyrylcarnitine HMDB13127 Lipid Fatty Acid Metabolism 0.0003 1.993
Oleoylcarnitine HMDB05065 Lipid 0.0009 1.284
Stearoylcarnitine HMDB00848 Lipid 0.0010 1.387
Palmitoylcarnitine HMDB00222 Lipid 0.0121 0.930
Myristoylcarnitine HMDB05066 Lipid 0.0050 0.854
Myristoleoylcarnitine* Lipid 0.0064 0.536
Laurylcarnitine HMDB02250 Lipid 0.0002 0.648
Octanoylcarnitine HMDB00791 Lipid 0.037 0.423
Acetylcarnitine HMDB00201 Lipid 0.0088 0.696
2-methylbutyrylcarnitine (C5) HMDB00378 Amino Acid BCAA Metabolism 0.0194 -0.828
Tiglylcarnitine HMDB02366 Amino Acid 4.83 e-05 -0.347
Isovalerylcarnitine HMDB00688 Amino Acid 5.76 e-05 -1.716
Propionylcarnitine HMDB00824 Amino Acid 5.81 e-05 -1.796
2-methylmalonyl carnitine HMDB13133 Amino Acid 2.69 e-14 -1.111
Isobutyrylcarnitine HMDB00736 Amino Acid 0.0030 -1.043
Succinylcarnitine Energy TCA Cycle 1.51 e-05 -1.911
Glutarylcarnitine (C5) HMDB13130 Amino Acid Lysine Metabolism 0.0083 -0.886
https://doi.org/10.1371/journal.pone.0184022.t007
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a role in intermediary metabolism in the regulation of glucose lipid and energy metabolism
[19–22] and a work in a GLUT1-DS mouse model revealed diminished cerebral lipid synthesis
in these mice [23,24]. Isocitrate and glycerol-3-phosphate are known to play roles in cellular
energetics and their biochemicals, or a ratio of them given they change in opposite directions,
may be biomarkers of disease.
Energy failure has been proved in GLUT1-DS astrocytes [24]. TCA metabolites are globally
reduced in GLUT1-DS patients and succinylcarnitine (C4) which arises from the TCA cycle
intermediate succinyl-CoA [25] was significantly lower in our cohort (Table 7). Energy
impairment is also supported by the recently proved clinical therapeutic efficacy in GLUT1-DS
of triheptanoin which is a dietary supplement that replenishes key substrates to the TCA cycle
in the brain [26]. We detected 2-aminoheptanoate at significantly higher levels in GLUT1-DS
patients (average z-score = 1.4411, p<0.01). Heptanoate, a direct product of triheptanoin
metabolism, can easily cross the blood-brain barrier via monocarboxylate transporters and
enhance the effect of ketones as fuel to the TCA cycle in the brain [27, 28]. Specifically, 2-ami-
noheptanoate can be metabolized to two molecules of acetyl-CoA and one molecule of propio-
nyl-CoA. Propionyl-CoA then can be metabolized to succinyl-CoA, an intermediate of the
TCA cycle. We speculate that high 2-aminoheptanoate in GLUT1-DS patients might be a com-
pensatory neurochemical mechanism for recovering energy homeostasis induced by ketone
bodies.
The KD induced differences in plasma biochemical profiles in lipid, carbohydrate, and
amino acid related compounds (Tables 3 and 4). The type of KD can differ in fatty acid content
and composition, thereby affecting the levels of free fatty acids in the bloodstream [29]. Within
the lipid superfamily, long-chain fatty acids, phospholipids, acylcarnitines, and sphingolipids
showed significant perturbations. Medium-chain fatty acids such as octanoic acid and decanoic
acid acids have been found to be elevated in the plasma of GLUT1-DS patients on KD [30].
Decanoate showed no changes in our subjects diagnosed with GLUT1-DS, and octanoate
showed reduced levels in subjects diagnosed with GLUT1-DS (S2 Table). This profile suggests
the KD consumed by these subjects did not contain medium chain triglycerides. Klepper et al.
analyzed essential fatty acid levels in the plasma and CSF of 18 GLUT1-deficient patients con-
suming a ketogenic diet and revealed their respective levels versus control patients could be
maintained over the course of several months [31].
Low to normal blood glucose levels in GLUT1-DS have been reported [32]. In our cohort,
all GLUT1-DS patients showed significantly lower levels of different carbohydrate compounds;
the most significant were those of maltose, sucrose, lactose, glucose, and mannitol/sorbitol
(Table 4). Previous reports have suggested that a KD may decrease blood glucose level [33,34].
The brain can utilize ketones as a source of energy in the presence of low levels or absence
of glucose. Ketones can be ingested through diet and produced through the metabolism of lip-
ids. Because of this, ketone levels vary according to the dietary regimen, energy balance, physi-
cal activities and long-term side effects (e.g. elevated blood lipids, growth retardation) [7]. The
neuroprotective effects of ketone bodies rely on alternative brain energy fuel recovery in lipid
biosynthesis and influence on neuronal excitability [35,36], although the exact mechanism(s)
of action of KD along with biochemical changes that are KD-related are still unknown, and
KD is not fully effective in all GLUT1-DS patients [7]. Marin-Valencia et al. showed GLUT1-
DS mice had elevated plasma fatty acids and ketone bodies [23]. Although glucose is the main
energy source for neurons, cells can also utilize ketones, lactate, pyruvate, glycerol and some
amino acids as alternative substrates [37]. Brain amino acids such as glutamate, glutamine,
GABA, adenosine, pyruvate and aspartate were preserved in CSF of GLUT1-DS in line with
other reports [23]. Specific KD metabolites include BHBA and 3-hydroxybutyrylcarnitine, as
reflected in the plasma from 6 patients with GLUT1-DS on KD. Other potential KD-associated
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Fig 2. Plasma biochemical profiles of GLUT1-DS patients on KD. A) Low plasma free carnitine in
GLUT1-DS patients on ketogenic diet. Box-plot of free and grouped bound-carnitine compounds z-scores for 6
patients with GLUT1-DS on ketogenic diet. Low levels of free carnitine were detected, while all carnitine
conjugates showed higher levels in GLUT1-DS patients on ketogenic diet. B) Carnitine-bound metabolites are
elevated in plasma of patients on ketogenic diet. Box-plot of free carnitine and specific carnitine-derived
compound for 6 patients with GLUT1-DS on ketogenic diet. Higher levels of 3-hydroxybutyrylcarnitine is
detected in face of low levels of other carnitine derived compounds (isovalerylcarnitine. 2-methylbutyrylcarnitine.
2-methylmalonyl carnitine. propionylcarnitine. succinylcarnitine) in GLUT1-DS patients on ketogenic diet.
https://doi.org/10.1371/journal.pone.0184022.g002
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metabolites may include: N-acetylglycine, 2-hydroxyisobutyrate, nonadecanoate, alpha-keto-
butyrate, 3-hydroxylaurate, 10-nonadecenoate, margarate, 15-methylpalmitate and 2-amino-
heptanoate since they showed significant high values in our KD patients. In addition to dietary
intervention with a ketogenic diet, plasma from subjects in a fasted state will have elevated
ketone bodies and elevated free fatty acids, but the patients in this study were randomly sam-
ples and thus, did not have blood taken during a fasted state. Margarate influences the fatty
acid network involving nonadecanoate, palmitate and heptadecenoate [38]. 3-hydroxybutyrate
and 3-hydroxybutyrylcarnitine can be used as plasma biomarkers for personalized monitoring
of individuals and for optimization of their diet.
L-carnitine regulates the flux substrate and energy balance across cell membranes by modu-
lating the transport of long-chain fatty acids into mitochondria [39,40]. Free carnitine levels
were significantly lower in GLUT1-DS patients on KD (p = 0.01) (Table 6, Fig 2A and 2B) con-
sistent with those results obtained by other who have examined gradual carnitine depletion
with long-term KD treatment [39]. The overall profiles in Table 3 and Table 7 are indicative of
the consumption of carnitine and the metabolism of fatty acids through β-oxidation. Ketosis
induces chronic formation of acyl-carnitine derivatives causing a dip of free carnitine
[39,41,42]. Carnitine deficiency will impair oxidation of fatty acids and ketone production
[39]. However, the need for carnitine supplementation in patients on KD remains controver-
sial [39,41]. Based on our results and the low risk associated with L-carnitine supplementation,
we suggest oral supplementation with carnitine for GLUT1-DS patients on KD for dietary
intervention with a starting dose of 10–50 mg/kg per day [41].
The present study is, to the best of our knowledge, the first to investigate metabolomics
perturbation in GLUT1-DS patients. The emerging application of metabolomics in clinical
practice could contribute to an informative diagnosis and may provide insights into the patho-
mechanisms of IEMs, potentially broadening therapeutic choices, as those identified in the
analysis of CSF and plasma from subjects diagnosed with GLUT1-DS. Overall, metabolomics
has revealed multiple dysregulated metabolites in several pathways in the CSF and plasma of
patients diagnosed with GLUT1-DS. From this perspective, metabolomics may provide new
insights into the mechanisms regulating GLUT1 function and may open, with the collection of
additional data from subjects diagnosed with GLUT1-DS or other glucose transporter defi-
ciencies, new avenues of treatment.
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